Introduction
Liver mass biopsy is a procedure performed to obtain tissue samples from an abnormal lesion or mass identified within the liver. The liver is one of the most common sites of both primary malignancy and metastatic disease in the body and the accurate characterization of a hepatic mass is a critical step in the oncological diagnostic pathway. While cross-sectional imaging including ultrasound, CT and MRI can provide valuable information about the nature of a liver lesion, tissue sampling remains the gold standard for definitive diagnosis in the majority of cases. Performed under real-time imaging guidance by an experienced interventional radiologist, liver mass biopsy is a precise, safe and minimally invasive procedure that delivers high-quality tissue through a small skin puncture, avoiding the need for open surgical biopsy in virtually all clinical scenarios.
Understanding Liver Masses
The liver can harbor a wide variety of benign and malignant lesions and distinguishing between them is essential for appropriate patient management. Benign hepatic masses include simple cysts, hemangiomas, focal nodular hyperplasia and hepatocellular adenomas. Malignant liver masses include hepatocellular carcinoma, which arises from the liver’s own hepatocyte cells and is the most common primary liver malignancy, intrahepatic cholangiocarcinoma arising from the bile ducts and metastatic deposits from colorectal, breast, lung, pancreatic and other primary cancers. Metastatic liver disease is in fact far more common than primary liver malignancy in most Western populations. On imaging, many liver lesions have characteristic features that allow a confident diagnosis without biopsy, such as the typical enhancement pattern of a hemangioma or the arterial enhancement and washout pattern of hepatocellular carcinoma in a cirrhotic liver. However, when imaging features are indeterminate, atypical or insufficient to make a confident diagnosis, tissue biopsy becomes indispensable.
Indications for the Procedure
Liver mass biopsy is indicated in a range of clinical situations where tissue characterization is required to guide management. Common indications include a newly detected hepatic mass with indeterminate imaging features that cannot be confidently diagnosed as benign, a suspected hepatocellular carcinoma in a non-cirrhotic liver where imaging criteria for diagnosis are not met, tissue confirmation of metastatic liver disease in a patient with a known primary malignancy, characterization of an intrahepatic mass where cholangiocarcinoma is suspected, evaluation of a liver lesion in a patient with no known primary malignancy where the diagnosis would determine the entire subsequent management pathway and molecular or genetic profiling of hepatic tumor tissue to guide targeted therapy or clinical trial eligibility. In patients with diffuse hepatic disease such as cirrhosis, hepatitis or infiltrative malignancy, liver biopsy may also be performed to assess the degree of fibrosis or the extent of tumor infiltration.
Pre-Procedure Preparation
Thorough pre-procedure preparation is essential for the safe and successful biopsy of a liver mass. The interventional radiologist begins by carefully reviewing all available cross-sectional imaging including ultrasound, CT with contrast and MRI with hepatobiliary contrast agents where available, to fully characterize the target lesion and plan the safest biopsy approach. The size, location and depth of the mass within the liver are assessed, along with its relationship to the major hepatic vessels, bile ducts, the gallbladder and the adjacent diaphragm and pleural space. A biopsy site within the viable, non-necrotic portion of the mass is selected to maximize diagnostic yield. Pre-procedure blood tests including a full blood count, coagulation profile and liver function tests are obtained. Any coagulopathy is corrected before the procedure and anticoagulant or antiplatelet medications are reviewed and appropriately managed. The patient is kept fasting for a few hours before the procedure. Intravenous access is secured and the procedure is performed with local anesthetic supplemented by intravenous sedation and analgesia where required. Informed consent is obtained after a thorough explanation of the purpose, technique, expected benefits and potential risks.
How the Procedure is Performed
The patient is positioned on the procedure table, most commonly in the supine or left lateral decubitus position depending on the location of the target mass within the liver. The skin overlying the planned puncture site, typically the right flank or subcostal region, is cleaned with antiseptic solution and sterile drapes are applied. Real-time imaging guidance is used to confirm the position of the target mass and plan the needle trajectory, which is carefully selected to avoid the major hepatic veins, portal vein branches, bile ducts, gallbladder and the pleural space superiorly.
Local anesthetic is administered generously to the skin, subcutaneous tissues and liver capsule along the planned needle track. The needle approach is designed to pass through a small cuff of normal liver parenchyma before entering the mass where anatomically feasible. This technique, sometimes referred to as a transhepatic approach, reduces the risk of hemorrhage and minimizes the theoretical risk of tumor seeding along the needle track by ensuring that the biopsy channel is contained within the liver parenchyma rather than passing directly through the peritoneal cavity.
A coaxial biopsy system is most commonly employed. An outer introducer needle is advanced to the margin of the target lesion under continuous real-time imaging guidance. Through this coaxial system, a spring-loaded core biopsy needle is passed and rapidly fired to obtain a cylindrical tissue core from within the mass. The coaxial approach allows multiple samples to be collected through a single skin puncture, minimizing procedural risk. Typically two to four cores are obtained from the viable peripheral portion of the lesion, avoiding any central necrotic areas that would yield non-diagnostic tissue. Specimens are submitted for routine histopathology, immunohistochemistry and any additional molecular, genetic or microbiological studies indicated by the clinical context. In cases where hepatocellular carcinoma is suspected, specific immunohistochemical markers such as glypican-3, arginase-1 and HepPar-1 are requested. For metastatic lesions, a broad immunohistochemical panel is applied to identify the likely primary tumor site. After all samples have been obtained, the needle is withdrawn and hemostasis is achieved at the puncture site.
Post-Procedure Care and Recovery
Following the biopsy, the patient is monitored in a recovery area for a minimum of two to four hours, with regular assessment of vital signs, pain levels and the puncture site. This observation period is longer than for superficial biopsies given the vascular nature of the liver and the potential for delayed hemorrhage. Most patients are discharged home the same day once they are comfortable and clinically stable. Patients are advised to rest for the remainder of the day, avoid strenuous activity and heavy lifting for forty-eight hours, and seek medical attention if they develop worsening right upper quadrant or shoulder tip pain, fever, significant abdominal swelling or any signs of bleeding. Pathology results are generally available within three to seven working days, with more complex molecular studies taking additional time depending on the investigations required.
Risks and Complications
Liver mass biopsy is a well-established procedure with an excellent safety record when performed by an experienced interventional radiologist under imaging guidance. The most clinically relevant complication is hemorrhage, which occurs in a significant form in less than one percent of cases. Minor bleeding at the puncture site or a small subcapsular hematoma is more common but typically resolves without intervention. Other potential complications include pain, which is common and usually managed with simple analgesia, pneumothorax from inadvertent pleural transgression during biopsy of superiorly located lesions, bile leak, infection and vasovagal reactions. The theoretical risk of tumor seeding along the needle track is extremely rare in modern practice with fine-gauge coaxial needle systems and is generally not considered a contraindication to biopsy in clinical guidelines.
Diagnostic Accuracy and Clinical Impact
The diagnostic accuracy of imaging-guided core needle biopsy of liver masses is consistently high, with reported sensitivity and specificity exceeding ninety percent in most published series. In the era of precision oncology, the tissue obtained from liver mass biopsy serves not only to establish a histological diagnosis but also as the substrate for comprehensive molecular profiling. Identification of specific mutations such as IDH1 and IDH2 in cholangiocarcinoma, BRAF mutations in metastatic colorectal cancer and receptor expression profiles in metastatic breast cancer directly influences the selection of targeted therapies, immunotherapy agents and eligibility for clinical trials. A single well-performed liver mass biopsy can therefore shape an entire cancer treatment journey.
Conclusion
Liver mass biopsy performed under real-time imaging guidance is an essential and highly effective procedure in the management of patients with hepatic lesions. By delivering precise, high-quality tissue samples through a minimally invasive technique, the interventional radiologist provides the definitive pathological diagnosis upon which all subsequent clinical decisions depend. With an excellent safety profile, high diagnostic accuracy and the capacity to support advanced molecular analysis, it remains one of the most important and frequently performed procedures in interventional radiology and a cornerstone of modern hepatic oncology practice.